Accessibility Menu
 
Arbutus Biopharma logo

Arbutus Biopharma

(NASDAQ) ABUS

Current Price$4.61
Market Cap$922.66M
Since IPO (2010)-33%
5 Year+47%
1 Year+46%
1 Month+8%

Arbutus Biopharma Financials at a Glance

Market Cap

$922.66M

Revenue (TTM)

$14.08M

Net Income (TTM)

$33.50M

EPS (TTM)

$-0.18

P/E Ratio

-26.91

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$4.61

Volume

874,100

Open

$4.71

Previous Close

$4.60

Daily Range

$4.59 - $4.71

52-Week Range

$2.94 - $5.10

ABUS: Motley Fool Moneyball Superscore

35

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arbutus Biopharma

Industry

Biotechnology

Employees

19

CEO

Lindsay Androski, CFA, MBA

Headquarters

Warminster, PA 18974, US

ABUS Financials

Key Financial Metrics (TTM)

Gross Margin

36%

Operating Margin

-3%

Net Income Margin

-2%

Return on Equity

-39%

Return on Capital

-55%

Return on Assets

-35%

Earnings Yield

-3.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$922.66M

Shares Outstanding

195.48M

Volume

874.10K

Short Interest

0.00%

Avg. Volume

2.20M

Financials (TTM)

Gross Profit

$13.72M

Operating Income

$27.05M

EBITDA

$26.69M

Operating Cash Flow

$39.64M

Capital Expenditure

$0.00

Free Cash Flow

$39.64M

Cash & ST Invst.

$91.47M

Total Debt

$4.19M

Arbutus Biopharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.05M

-33.2%

Gross Profit

$1.04M

+114.4%

Gross Margin

98.95%

N/A

Market Cap

$922.66M

N/A

Market Cap/Employee

$20.97M

N/A

Employees

44

N/A

Net Income

$3.76M

+70.0%

EBITDA

$7.63M

+50.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$87.28M

-28.1%

Accounts Receivable

$1.75M

-27.5%

Inventory

$0.00

N/A

Long Term Debt

$3.64M

+351.7%

Short Term Debt

$547.00K

+13.3%

Return on Assets

-35.41%

N/A

Return on Invested Capital

-55.42%

N/A

Free Cash Flow

$4.68M

+55.0%

Operating Cash Flow

$4.68M

+54.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KURAKura Oncology, Inc.
$9.78+1.03%
SPRYARS Pharmaceuticals, Inc.
$8.18+0.00%
SVRASavara Inc.
$5.61-2.94%
SEPNSepterna, Inc.
$26.86+2.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.29-0.04%
NOKNokia
$10.60+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$58.08-0.01%
TSLATesla
$392.50-0.02%

Questions About ABUS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.